Spotlight On Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that primarily affects the joints and can lead to progressive joint damage and functional impairment. And because the course of RA can vary from patient to patient, timely assessment and ongoing disease management are important considerations.
Explore our Spotlight On Rheumatoid Arthritis series for expert perspectives and clinical insights on diagnosis, treatment decision-making, and strategies for long-term patient care.
1-9 of 9
Identifying and Diagnosing RA-Associated Interstitial Lung Disease
Living RheumIdentifying and Diagnosing RA-Associated Interstitial Lung Disease
Bryant England, MD, PhD
Choosing a JAK Inhibitor for Rheumatoid Arthritis
Living RheumChoosing a JAK Inhibitor for Rheumatoid Arthritis
Roy Fleischmann, MD, MACR
Shared Decision-Making in Rheumatoid Arthritis Care
Living RheumShared Decision-Making in Rheumatoid Arthritis Care
Elena Myasoedova, MD, PhD
Beyond the Black Box: JAK Inhibitor Safety in RA
Living RheumBeyond the Black Box: JAK Inhibitor Safety in RA
Roy Fleischmann, MD, MACR
SGLT2 Inhibitors Linked to Lower RA Risk Versus Sulfonylureas in T2D
Living RheumSGLT2 Inhibitors Linked to Lower RA Risk Versus Sulfonylureas in T2D
Navigating Treatment Decisions for Rheumatoid Arthritis: Key Factors to Consider
Living RheumNavigating Treatment Decisions for Rheumatoid Arthritis: Key Factors to Consider
Robin Dore, MD
- advertisement
Rheumatoid Arthritis Care: Examining the Current Landscape and Emerging Research
Living RheumRheumatoid Arthritis Care: Examining the Current Landscape and Emerging Research
Robin Dore, MD
How Biosimilars Can Enhance the Lives—and Savings—of Rheumatoid Arthritis Patients
Clinician's RoundtableHow Biosimilars Can Enhance the Lives—and Savings—of Rheumatoid Arthritis Patients
The Safety and Efficacy of Biosimilars in the Treatment of Rheumatoid Arthritis
Spotlight on BiosimilarsThe Safety and Efficacy of Biosimilars in the Treatment of Rheumatoid Arthritis